BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 35441134)

  • 1. β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns.
    Jiang C; Wang Q; Xie S; Chen Z; Fu L; Peng Q; Liang Y; Guo H; Guo T;
    Brain Commun; 2022; 4(2):fcac084. PubMed ID: 35441134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers.
    Tosun D; Veitch D; Aisen P; Jack CR; Jagust WJ; Petersen RC; Saykin AJ; Bollinger J; Ovod V; Mawuenyega KG; Bateman RJ; Shaw LM; Trojanowski JQ; Blennow K; Zetterberg H; Weiner MW
    Brain Commun; 2021; 3(2):fcab008. PubMed ID: 33842885
    [No Abstract]   [Full Text] [Related]  

  • 3. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
    Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles.
    Pascoal TA; Therriault J; Benedet AL; Savard M; Lussier FZ; Chamoun M; Tissot C; Qureshi MNI; Kang MS; Mathotaarachchi S; Stevenson J; Hopewell R; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P
    Brain; 2020 Sep; 143(9):2818-2830. PubMed ID: 32671408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.
    Gordon BA; Friedrichsen K; Brier M; Blazey T; Su Y; Christensen J; Aldea P; McConathy J; Holtzman DM; Cairns NJ; Morris JC; Fagan AM; Ances BM; Benzinger TL
    Brain; 2016 Aug; 139(Pt 8):2249-60. PubMed ID: 27286736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
    Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.
    Lowe VJ; Wiste HJ; Senjem ML; Weigand SD; Therneau TM; Boeve BF; Josephs KA; Fang P; Pandey MK; Murray ME; Kantarci K; Jones DT; Vemuri P; Graff-Radford J; Schwarz CG; Machulda MM; Mielke MM; Roberts RO; Knopman DS; Petersen RC; Jack CR
    Brain; 2018 Jan; 141(1):271-287. PubMed ID: 29228201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is tau in the absence of amyloid on the Alzheimer's continuum?: A study of discordant PET positivity.
    Weigand AJ; Bangen KJ; Thomas KR; Delano-Wood L; Gilbert PE; Brickman AM; Bondi MW;
    Brain Commun; 2020; 2(1):fcz046. PubMed ID: 32051933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between quantitative [
    Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM
    Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.
    Palmqvist S; Mattsson N; Hansson O;
    Brain; 2016 Apr; 139(Pt 4):1226-36. PubMed ID: 26936941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
    Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
    Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
    JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
    Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
    JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain alterations in the early Alzheimer's continuum with amyloid-β, tau, glial and neurodegeneration CSF markers.
    Salvadó G; Shekari M; Falcon C; Operto G; Milà-Alomà M; Sánchez-Benavides G; Cacciaglia R; Arenaza-Urquijo E; Niñerola-Baizán A; Perissinotti A; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Molinuevo JL; Zetterberg H; Blennow K; Suárez-Calvet M; Gispert JD;
    Brain Commun; 2022; 4(3):fcac134. PubMed ID: 35702732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.
    Burnham SC; Iaccarino L; Pontecorvo MJ; Fleisher AS; Lu M; Collins EC; Devous MD
    Brain Commun; 2024; 6(1):fcad305. PubMed ID: 38187878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
    Ossenkoppele R; Pichet Binette A; Groot C; Smith R; Strandberg O; Palmqvist S; Stomrud E; Tideman P; Ohlsson T; Jögi J; Johnson K; Sperling R; Dore V; Masters CL; Rowe C; Visser D; van Berckel BNM; van der Flier WM; Baker S; Jagust WJ; Wiste HJ; Petersen RC; Jack CR; Hansson O
    Nat Med; 2022 Nov; 28(11):2381-2387. PubMed ID: 36357681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.